Greenbrook
Greenbrook operates a network of outpatient mental wellness centers across 15+ U.S. states delivering NeuroStar TMS therapy and SPRAVATO esketamine treatment to adults with treatment-resistant depression, OCD, and MDD with suicidal ideation, accepting major insurance, Medicare, and Medicaid.
- Company typePrivate
- Founded2018
- HeadquartersMclean, United States
- Headcount101–250
- GTM typeB2C
- OfferingServices
What Greenbrook does
Greenbrook operates a national network of outpatient mental wellness centers across 15+ U.S. states delivering two FDA-regulated treatments for treatment-resistant depression, OCD, and major depressive disorder with suicidal ideation: NeuroStar Transcranial Magnetic Stimulation (TMS) therapy and SPRAVATO (esketamine) nasal spray. NeuroStar TMS is an FDA-cleared, non-invasive, non-medication procedure that delivers focused electromagnetic pulses to the left dorsolateral prefrontal cortex via coils placed against the scalp, typically administered 5 days per week for 6-9 weeks (30-36 sessions of 18-45 minutes each). SPRAVATO is an FDA-approved esketamine nasal spray self-administered under supervision at REMS-certified centers, with a structured induction, maintenance, and long-term maintenance dosing protocol and mandatory 2-hour post-dose observation. Greenbrook reports cumulative lifetime volume above 1.61 million treatments and cites 83% improvement and 62% full remission in real-world NeuroStar outcomes, with over 2,200 five-star Google reviews.
The business is fundamentally a multi-site specialty healthcare services operator. Greenbrook acquires patients predominantly through direct-to-consumer channels — its website, paid social, SEO content, PHQ-9/PHQ-10 self-assessment quizzes, and a free consultation line (855-940-4867) staffed by Consult Coordinators who review history in-person, by video, or by phone. The company handles insurance verification, billing, and appeals on behalf of patients across most major commercial plans plus Medicare and Medicaid at various sites, and offers CareCredit as a self-pay financing option. Following the December 2024 acquisition by Neuronetics for approximately $42 million, Greenbrook operates as a wholly-owned subsidiary and now sells fee-based patient support services (PHQ-10 processing, TMS consultations, scheduling) to channel partners, including an exclusive three-year TMS device and services partnership with Elite DNA Behavioral Health covering 30+ Florida and Virginia clinics. The Neuronetics board is publicly evaluating separation of the device and clinic businesses.
Greenbrook firmographics
Firmographics- Name
- Greenbrook
- Legal name
- Greenbrook TMS Inc.
- Website
- https://greenbrooktms.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Acquired
- Headcount range
- 101–250 employees
- Short description
- Greenbrook operates a network of outpatient mental wellness centers across 15+ U.S. states delivering NeuroStar TMS therapy and SPRAVATO esketamine treatment to adults with treatment-resistant depression, OCD, and MDD with suicidal ideation, accepting major insurance, Medicare, and Medicaid.
- Ownership category
- akta.pro rank
Greenbrook industry classification
Industry- Product category
- Outpatient Mental Health Treatment Services
- NAICS
- Outpatient Mental Health and Substance Abuse Centers (621420), Offices of Physicians, Mental Health Specialists (621112)
- SIC
- Services-Offices & Clinics Of Doctors Of Medicine (8011)
- akta.pro primary industry
- Outpatient Mental Health Clinics & Counseling Centers (HLAFACAA)
- akta.pro secondary industry
- Outpatient Mental Health & Counseling Clinics (HLAFABAC)
Keywords
Where Greenbrook is headquartered
LocationHeadquarters
- HQ city
- Mclean
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Greenbrook business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure, Supply Chain
Revenue model
- Healthcare Services Revenue: Greenbrook generates revenue by operating outpatient mental health treatment centers providing NeuroStar TMS therapy and SPRAVATO esketamine nasal spray treatments. Patients pay through insurance coverage (most major insurance plans, Medicare, Medicaid) or self-pay. The company handles all insurance billing and paperwork on behalf of patients.
- Fee-Based Patient Support Services: Following the Neuronetics acquisition, Greenbrook provides expanded fee-based patient support services including PHQ-10 processing, TMS consultations, and scheduling to partner healthcare providers (e.g., Elite DNA Behavioral Health) as part of exclusive TMS device partnership agreements.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Insurance-covered TMS and esketamine treatment |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels8 records
Greenbrook product offering
Product offeringCore offering
Greenbrook operates a national network of outpatient mental wellness centers that deliver two FDA-regulated treatments for depression: NeuroStar TMS Therapy (FDA-cleared transcranial magnetic stimulation) and SPRAVATO (esketamine) nasal spray therapy. The company handles insurance verification and billing on behalf of patients and offers free consultations in person, by phone, or via video conference to assess treatment eligibility.
Product overview
Greenbrook Mental Wellness operates a network of outpatient mental wellness centers across the United States providing two FDA-regulated treatments for depression: NeuroStar TMS (Transcranial Magnetic Stimulation) therapy and SPRAVATO® (esketamine) nasal spray. NeuroStar TMS is an FDA-cleared non-invasive treatment using electromagnetic pulses to stimulate specific brain regions associated with mood regulation. SPRAVATO® is an FDA-approved ketamine-based nasal spray for treatment-resistant depression. The company accepts most major insurance plans including Medicare and Medicaid, and has delivered over 1.61 million treatments to patients. The company was acquired by Neuronetics, Inc. (NASDAQ: STIM) in December 2024.
Differentiator
Problem solved
Functional benefit
Products and services
- NeuroStar TMS Therapy
Quantifiable outcome
- 83% of patients who completed NeuroStar TMS therapy experienced measurable depression relief
- +5 more outcomes
Companies that use Greenbrook
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles4 records
Greenbrook technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
Feature3 records
Greenbrook partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- Neuronetics Inc.coreNeuronetics acquired Greenbrook TMS in December 2024 for approximately $42 million. Neuronetics is a medical technology firm focused on neurohealth disorders, manufacturing the NeuroStar Advanced Therapy System and operating Greenbrook TMS treatment centers across the United States. The Board is evaluating potential separation of the NeuroStar and Greenbrook businesses to unlock shareholder value. Q1 2026 earnings reflect growth across both NeuroStar systems and clinic operations following the acquisition.
- EvernorthminorEvernorth removed prior authorization requirements for transcranial magnetic stimulation (TMS) services for its contracted providers. This policy change expands access to TMS treatments for mental health conditions like depression, PTSD, and OCD for patients covered by Evernorth insurance plans.
- Elite DNA Behavioral HealthcoreExclusive three-year agreement making Neuronetics/Greenbrook the sole provider of transcranial magnetic stimulation devices across Elite DNA's 30+ clinic locations in Florida and Virginia. The partnership leverages Greenbrook TMS's operational platform to provide expanded fee-based patient support services including PHQ-10 processing, TMS consultations, and scheduling, allowing Elite DNA to focus on enhancing patient experience. The expanded partnership launched as a pilot in Q4 2025 with plans to expand in 2026.
- American Foundation for Suicide Prevention (AFSP)minorGreenbrook supports the American Foundation for Suicide Prevention, a non-profit established in 1987 that funds scientific research, educates the public about mental health and suicide prevention, advocates for public policies in mental health and suicide prevention, and supports survivors of suicide loss and those affected by suicide.
- This Is My BraveminorGreenbrook supports This Is My Brave, a non-profit organization that gives those living with mental illness a platform to share the stories of their struggles and recoveries through original stories, songs, and poems performed in front of a live audience.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
Greenbrook competitors and assessment
Company assessmentBroad incumbents
- Neuronetics: Neuronetics acquired Greenbrook in December 2024 and now operates the combined device (NeuroStar) and clinic platform. It is the parent and most direct strategic counterpart, given its shared manufacturing of the NeuroStar system and ownership of the clinic network.
Direct peers
- Achieve TMS: Acquired by Greenbrook in 2019 for $10.5M (per company history), Achieve TMS previously operated TMS treatment centers with a clinic-based depression model directly comparable to Greenbrook's pre-acquisition footprint and patient mix.
- Lyra Health: Employer-sponsored mental health benefit platform providing therapy, psychiatry, and coaching. Comparable business model in delivering mental health services to the commercially insured population and competing for the same payer-sponsored TRD patients.
- Spring Health: Employer-sponsored mental health platform offering therapy, medication, and care navigation. Comparable in targeting employer-insured populations and providing hybrid in-person/telehealth mental health care at scale.
Emerging players
- Talkiatry: Online psychiatry and medication management platform serving patients with depression and related conditions. Competes for the same treatment-resistant depression patient population, particularly on the medication-management side that often precedes referral to TMS/esketamine.
- Brightside Health: Telehealth depression treatment platform offering online psychiatry and therapy; overlap with Greenbrook on depression referrals and on serving patients who have failed first-line antidepressants, though delivered via telehealth rather than in-clinic modality.
- Cerebral: Online mental health provider offering medication management and therapy for depression and anxiety. Comparable as a DTC-fronted mental health brand targeting patients who have not responded to traditional treatments.
- Charlie Health: Provides intensive outpatient and virtual mental health programs primarily for adolescents and young adults with depression and anxiety. Comparable as a higher-acuity outpatient model for treatment-resistant patients in a non-residential setting.
- Two Chairs: In-person and virtual therapy provider operating outpatient clinics with an in-network insurance model. Comparable in combining outpatient clinic delivery with insurance billing and operational focus on improving therapy outcomes.
- Newport Healthcare: Operates residential and outpatient mental health treatment programs for adolescents and adults with depression and co-occurring disorders. Comparable in clinical specialty around treatment-resistant mood disorders, though delivered at higher acuity (residential/inpatient).
Market position
Strengths4 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Greenbrook social profiles
Digital presenceGreenbrook compliance and trust
Trust signalCompliance4 records
Greenbrook financial estimates
Financial estimateRevenue estimate
Valuation estimate
Greenbrook leadership team
Management profileNumber of profiles
Profiles9 records
Greenbrook funding detail
Funding detailFunding overview
Funding rounds19 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Greenbrook M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Greenbrook
What does Greenbrook do?
Greenbrook operates a national network of outpatient mental wellness centers that deliver two FDA-regulated treatments for depression: NeuroStar TMS Therapy (FDA-cleared transcranial magnetic stimulation) and SPRAVATO (esketamine) nasal spray therapy. The company handles insurance verification and billing on behalf of patients and offers free consultations in person, by phone, or via video conference to assess treatment eligibility.
Is Greenbrook a public or private company?
Greenbrook is a private company. It is classified as corporate owned and is currently acquired.
When was Greenbrook founded?
Greenbrook was founded in 2018. It employs 101 to 250 people.
Where is Greenbrook based?
Greenbrook is headquartered in Mclean, United States, in the North America region.
How does Greenbrook make money?
Two revenue lines are on record. Healthcare Services Revenue is the primary driver. The others are fee-Based Patient Support Services.
Who are Greenbrook's main competitors?
Neuronetics is listed as a broad incumbent. Direct peers are Achieve TMS, Lyra Health and Spring Health. Emerging players are Talkiatry, Brightside Health, Cerebral, Charlie Health, Two Chairs and Newport Healthcare.
Does Greenbrook have an API?
No public API is recorded for Greenbrook.
What industry is Greenbrook in?
Greenbrook's product category is Outpatient Mental Health Treatment Services. Its primary akta.pro industry code is HLAFACAA, Outpatient Mental Health Clinics & Counseling Centers, with a secondary code of HLAFABAC, Outpatient Mental Health & Counseling Clinics. Its NAICS code is 621420 and its SIC code is 8011.